Cenexi turnaround delay
Cenexi is still a few quarters away from a complete turnaround; Q2 will be impacted by extended summer shutdown.
high · management_commentaryGland Pharma Limited — Q1 FY25
Gland Pharma reported consolidated revenue of INR 14,070 million (+16% YoY), driven by 14% growth in the base business and Cenexi contribution.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. pricing pressure and product mix
U.S. market remains crowded; low-margin GPO contract and milestone income volatility could pressure margins.
medium · management_commentaryBiologics collaboration execution risk
Discussions for a strategic biologics collaboration are early-stage; may require significant investment with uncertain timeline.
medium · analyst_questionFosun stake sale overhang
Fosun sold a large stake in the quarter; management has no visibility on future share sales, which could impact sentiment.
medium · analyst_question